BrainsWay to Report Third Quarter Financial Results on November 16, 2022
BrainsWay Ltd. (NASDAQ: BWAY) will release its third quarter financial results and operational highlights on November 16, 2022, before U.S. market opening. A conference call scheduled for 8:30 AM ET will provide insights into the company’s performance and updates on business operations. BrainsWay specializes in noninvasive neurostimulation treatments for mental health disorders, with FDA-cleared technologies to treat major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The call will be accessible via dial-in and webcast.
- Leads in advanced noninvasive neurostimulation treatments.
- Three FDA-cleared indications demonstrating clinically proven efficacy.
- Committed to increasing global awareness and access to Deep TMS.
- None.
BURLINGTON, Mass. and JERUSALEM, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 16, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, November 16, 2022 |
| Time: | 8:30 AM Eastern Time |
| United States: | 1-877-407-3982 |
| International: | 1-201-493-6781 |
| Conference ID: | 13733745 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1577185&tp_key=a7877d8429 |
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Contacts:
BrainsWay:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
SAreglado@brainsway.com
Investors:
Brian Ritchie
LifeSci Advisors LLC
(212) 915-2578
britchie@lifesciadvisors.com
FAQ
What date will BrainsWay report its Q3 financial results?
What time is the BrainsWay conference call scheduled?
What is the stock symbol for BrainsWay?
How can I access the BrainsWay conference call?
